Sugi Predict

Sugi Predict / Compounds / SCHEMBL1896533

SCHEMBL1896533

SCHEMBL1896533

CCOC[C@H]1O[C@@H](n2ccc(N)nc2=O)[C@H](O)[C@@H]1O

nearest known ligand 0.70

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.70
▸ THRB P10828 1/20 0.70
▸ MTOR P42345 1/20 0.70
▸ MDM2 Q00987 1/20 0.70
▸ NCOA1 Q15788 1/20 0.70
▸ NCOA3 Q9Y6Q9 1/20 0.70
▸ L3MBTL1 Q9Y468 1/20 0.63
▸ TSHR P16473 1/20 0.60
▸ GLA P06280 1/20 0.60
▸ P2RY2 P41231 2/20 0.57
▸ ST6GAL1 P15907 5/20 0.55
▸ ADORA3 P0DMS8 1/20 0.52
▸ P2RY4 P51582 1/20 0.50
▸ P2RY6 Q15077 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9856687 1.00 LMNA (0.70) LMNATHRBMTORMDM2NCOA1
SCHEMBL15239323 0.91 LMNA (0.67) LMNATHRBMTORMDM2NCOA1
SCHEMBL3272277 0.89 LMNA (0.76) LMNATHRBMTORMDM2NCOA1
SCHEMBL2180648 0.88 LMNA (0.70) LMNATHRBMTORMDM2NCOA1
SCHEMBL12988159 0.88 LMNA (0.70) LMNATHRBMTORMDM2NCOA1
SCHEMBL2811458 0.88 LMNA (0.73) LMNATHRBMTORMDM2NCOA1
SCHEMBL14178411 0.88 LMNA (0.73) LMNATHRBMTORMDM2NCOA1
SCHEMBL17304691 0.88 LMNA (0.73) LMNATHRBMTORMDM2NCOA1
SCHEMBL383499 0.88 LMNA (0.73) LMNATHRBMTORMDM2NCOA1
SCHEMBL18231346 0.88 LMNA (0.73) LMNATHRBMTORMDM2NCOA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114533739-A Application of nucleoside analogue in preparing medicine for preventing or treating gastrointestinal tract diseases 兰州大学 2022-05-27 — — CN claimed
EP-4519436-A1 LOCALIZATION OF TRANS-SPLICING NUCLEIC ACID MOLECULES TO AND WITHIN THE CELLULAR NUCLEUS Tacit Therapeutics, Inc. (US) 2025-03-12 — — EP disclosed
US-20250074895-A1 CDK2 INHIBITORS AND METHODS OF MAKING AND USING SAME BLUEPRINT MEDICINES CORPORATION 2025-03-06 — — US disclosed
WO-2024133884-A2 OPTIMIZED TAILING OF MESSENGER RNA SANOFI (FR) 2024-06-27 — — WO disclosed
WO-2024102677-A1 CIRCULAR RNA COMPOSITIONS ORNA THERAPEUTICS, INC. (US) 2024-05-16 — — WO disclosed
WO-2024054867-A1 MODIFIED MOLECULAR BEACONS FOR IMPROVED DETECTION SPECIFICITY BECTON, DICKINSON AND COMPANY (US) 2024-03-14 — — WO disclosed
WO-2023215761-A1 LOCALIZATION OF TRANS-SPLICING NUCLEIC ACID MOLECULES TO AND WITHIN THE CELLULAR NUCLEUS TACIT THERAPEUTICS, INC. (US) 2023-11-09 — — WO disclosed
WO-2023115221-A1 IONIZABLE DILSULFIDE LIPIDS AND LIPID NANOPARTICLES DERIVED THEREFROM PROVIDENCE THERAPEUTICS HOLDINGS INC. (CA) 2023-06-29 — — WO disclosed
WO-2023084013-A1 COMPOSITIONS COMPRISING MODIFIED RNA ENCODING VEGF-A AND METHODS OF USE MODERNATX, INC. (US) 2023-05-19 — — WO disclosed
WO-2023061985-A2 COMPOSITIONS COMPRISING MODIFIED RNA ENCODING VEGF-A AND METHODS OF USE MODERNATX, INC. (US) 2023-04-20 — — WO disclosed
EP-2321332-B1 SELF-AVOIDING MOLECULAR RECOGNITION SYSTEMS IN DNA AMPLIFICATION BENNER STEVEN A (US) 2013-03-27 — — EP disclosed
US-20120190688-A1 APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES BRUNCKO MILAN (US) 2012-07-26 — — US disclosed
US-20110263599-A1 7-NONSUBSTITUTED INDOLE MCL-1 INHIBITORS ABBOTT LABORATORIES 2011-10-27 — — US disclosed
EP-2321332-A1 SELF-AVOIDING MOLECULAR RECOGNITION SYSTEMS IN DNA AMPLIFICATION Benner, Steven A. (US) 2011-05-18 — — EP disclosed
US-20100305118-A1 PYRIMIDINE INHIBITORS OF KINASE ACTIVITY ABBOTT LABORATORIES (US) 2010-12-02 — — US disclosed
WO-2010021702-A9 SELF-AVOIDING MOLECULAR RECOGNITION SYSTEMS IN DNA AMPLIFICATION BENNER STEVEN ALBERT (US) 2010-05-06 — — WO disclosed
US-20100099738-A1 POLYETHYLENE GLYCOL LIPID CONJUGATES AND USES THEREOF ABBOTT LABORATORIES (US) 2010-04-22 — — US disclosed
WO-2010021702-A1 SELF-AVOIDING MOLECULAR RECOGNITION SYSTEMS IN DNA AMPLIFICATION BENNER STEVEN ALBERT (US) 2010-02-25 — — WO disclosed
US-20030083281-A1 Antisense modulation of PKA regulatory subunit RII beta expression ISIS PHARMACEUTICALS INC. 2003-05-01 — — US disclosed
US-20030060437-A1 Antisense modulation of dual specific phosphatase 5 expression ISIS PHARMACEUTICALS INC. 2003-03-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100099738-A1 POLYETHYLENE GLYCOL LIPID CONJUGATES AND USES THEREOF LIPA, LIPG, LIPC LMNA 1949/4885THRB 1606/4885MTOR 4369/4885
US-20250074895-A1 CDK2 INHIBITORS AND METHODS OF MAKING AND USING SAME CDK2, CDK20, CDK2AP1 LMNA 1732/4885THRB 3235/4885MTOR 312/4885
US-20100305118-A1 PYRIMIDINE INHIBITORS OF KINASE ACTIVITY IGF1R, TK1, CDK2 LMNA 1836/4885THRB 418/4885MTOR 192/4885
US-20120190688-A1 APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES BCL2, BAX, BCL3 LMNA 2607/4885THRB 2265/4885MTOR 1387/4885
US-20110263599-A1 7-NONSUBSTITUTED INDOLE MCL-1 INHIBITORS MCL1, BCL2L1, API5 LMNA 1545/4885THRB 3644/4885MTOR 1956/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.